Roche Acquires Majority Interest in WuXi-Invested Foundation Medicine
January 12, 2015 at 04:50 AM EST
Roche will invest more than $1 billion to obtain a 56% stake in Foundation Medicine, a Boston company that offers a ground-breaking genomic test of cancer tumors. The FoundationOne® assay tests 343 regions of a tumor's genome to discover mutations and identify the best therapeutic option. WuXi PharmaTech's investment arm participated in Foundation's Series B round in 2012, and it partners with Foundation to provide the test in China. Roche's acquisition of Foundation provides WuXi with an early exit of its investment. More details.... Stock Symbols: (SIX: ROG) (NSDQ: FMI) (NYSE: WX) Share this with colleagues: // //